Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.

Details

Serval ID
serval:BIB_DE920AFA4790
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.
Journal
European journal of pediatrics
Author(s)
Ceppi F., Beck-Popovic M., Bourquin J.P., Renella R.
ISSN
1432-1076 (Electronic)
ISSN-L
0340-6199
Publication state
Published
Issued date
09/2017
Peer-reviewed
Oui
Volume
176
Number
9
Pages
1163-1172
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Over the last 50 years, collaborative clinical trials have reduced the number of children dying from pediatric cancer significantly. Unfortunately, certain tumor types have remained resistant to conventional surgical, radiotherapy and chemotherapy combinations, and relapsing and/or refractory disease remains associated with dismal outcomes. Recently, renewed attention has been given to the role for immunotherapies in pediatric oncology. In fact, these combine several attractive features, including (but possibly not limited to) the specificity for cancer cells, potentially in vivo persistence and longevity, and potency against refractory disease. In this narrative review designed for the academic pediatrician, we will concisely review the biological underpinnings behind the immunological therapy of pediatric neoplasms and illustrate the current humoral, cellular approaches, and novel drugs targeting the immune checkpoint, oncolytic viruses, and tumor vaccines. We will also comment on the future directions, challenges, and open questions faced by the field. What is Known: • Cancer immunotherapy drives immune cells and its humoral weaponry to eliminate tumor cells. • This occurs by recognizing antigens ideally expressed only on tumoral, but not normal/healthy, cells. What is New: • Clinical immunotherapy trials have shown responses in children with relapsing/refractory neoplasms. • Novel humoral/cellular immunotherapies, immune checkpoint inhibitors, oncolytic viruses, and tumor vaccines are currently being investigated in pediatric oncology.
Keywords
Adjuvants, Immunologic/therapeutic use, Antibodies, Monoclonal/therapeutic use, Antineoplastic Agents, Immunological/therapeutic use, Cancer Vaccines/therapeutic use, Child, Histocompatibility Antigens Class II/therapeutic use, Humans, Immunotherapy/methods, Immunotherapy/trends, Neoplasms/therapy, Oncolytic Virotherapy, T-Lymphocytes/drug effects, Cancer, Childhood, Immunotherapy, Pediatric hematology-oncology
Pubmed
Web of science
Create date
06/09/2017 12:49
Last modification date
20/08/2019 17:03
Usage data